摘要
目的:探讨伐昔洛韦联合咪喹莫特乳膏对预防频发性生殖器疱疹复发的疗效及安全性。方法:将2009年至2012年东莞市太平人民医院收治的102例频发性生殖器疱疹患者分为治疗组(52例)和对照组(50例)。两组均口服伐昔洛韦片450 mg,每日2次;治疗组加用咪喹莫特乳膏外用,每周3次;疗程均为3个月。观察两组患者治愈率、有效率和复发率。结果:治疗组痊愈率、总有效率略高于对照组,但差异无统计学意义(x^2=0.812,P>0.05)。治疗组总复发率(36.5%)低于对照组总复发率(82.0%),两组比较,差异有统计学意义(x^2=9.781,P<0.05)。两组治疗期间均未发生严重不良反应。结论:伐昔洛韦联合咪喹莫特乳膏比单用伐昔洛韦更能减低频发性生殖器疱疹的复发率,值得临床推广。
Objective: To investigate the efficacy and safety of valacyclovir and imiquimod cream for the treatment of recurrent genital herpes. Methods : Bet-seen 20039 and 2012, we allocated 102 patients with reeurrent genital herpes who were admitted to Taiping People' s Hospital of Dongguan to be treated with valacyclovir 450 mg twice daily alone (control group, n = 50) or in combination with topical imiquimod cream thrice weekly for 3 months (treatment group, n = 52 ). This entailed the comparison on the cure, effective and relapse rates. Results: The treatment group yielded numerically but not statistically higher cure and total effective rates than control group (both P 〉 0.05 ). However, treatment group was associated with a markedly lower rate of relapse (36.5% vs. 82%, χ2= 9. 781, P 〈 0.05 ) compared with control group. No serious adverse events were reported during the treatment. Conclusion : The combination of valacyclovir and imiquimod cream, compared with valacyclovir alone, is more and effective and safer for the treatment of recurrent genital herpes.
出处
《广州医学院学报》
2013年第6期58-59,共2页
Academic Journal of Guangzhou Medical College